# Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01153321** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 71 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- Lung Disease

## Interventions

- **DRUG:** AZD2423
- **DRUG:** AZD2423 Placebo

## Key facts

- **NCT ID:** NCT01153321
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2015-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01153321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01153321, "Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01153321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*